ER Dynamic Range Analyte Control
[HCL029]: ER Analyte ControlDR (2 unstained slides)
[HCL030]: ER Analyte ControlDR (5 unstained slides)
[HCL031]: ER Analyte ControlDR (1 cell microarray block)
Estrogen receptor has long been a target for treatment in breast cancer, with the greatest impact occurring with the introduction of Tamoxifen. Tamoxifen is a selective ER modulator (SERM) as it binds to ER causing dimerization yet does not induce the same recruitment of co-activators as the estrogens do. Newer therapies such as the aromatase inhibitors (AI) have demonstrated a greater effectiveness in both the adjuvant and metastatic setting.